Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin D3

This article was originally published in The Tan Sheet

Executive Summary

FDA grants approval for use of higher vitamin D3 levels as a nutrient supplement in cheese and cheese products, according to a final rule published in the Federal Register Nov. 16. Approval was granted following a food additive petition submitted by Kraft Foods. The petition requested that the previously allowed levels of vitamin D (89 IU per 100 g) be increased to 81 IU per 30 g. To support the safety of the proposed levels, Kraft submitted dietary intake estimates from current and proposed uses and from naturally occurring sources of vitamin D and compare the intake estimates to the tolerable upper intake level for vitamin D established by the Institute of Medicine, FDA notes. Use of vitamin D3 in certain meal replacement bars and beverages was approved in June by FDA in response to a citizen petition filed by Slim-Fast marketer Unilever (1"The Tan Sheet" July 4, 2005, p. 15)...

You may also be interested in...



Vitamin D3 Approved For Meal Replacement Beverages, Bars

FDA approved vitamin D3 as a food additive in certain functional foods for weight management in a final rule effective June 29

Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove

Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.

ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test

After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel